Male
Febrile Neutropenia (Pediatric)
Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy, defined by fever occurring in the context of neutropenia. Prompt recognition and treatment are essential to reduce morbidity and mortality. This algorithm focuses on "high-risk" FN as defined in the ‘Early versus Late Stopping of Antibiotics in high-risk FN’ (ELSA-FN) randomised control trial as expected absolute neutrophil count (ANC) <500 cells/mm3 for ≥7 days.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Functional seizures
Algorithm to detect functional seizures, also known as:
Psychogenic nonepileptic seizures
Nonepileptic attack disorder
Pseudoseizures
Hystero-epilepsy
Conversion disorder with seizures
Dissociative Seizures
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Gastroesophageal Reflux Disease (GERD) Phenotype Algorithm
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Hearing Loss
Phenotype Description: individuals with sensorineural hearing loss (SNHL)
Below are algorithms used to identify individuals with SNHL at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:
Wei-Qi Wei at wei-qi.wei@vanderbilt.edu or Joshua Denny at josh.denny@vanderbilt.edu
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
Herpes Zoster
Herpes zoster, also known as zoster or shingles, is caused by a virus called varicella zoster virus (VZV). Initial infection with the virus causes chickenpox. After chickenpox resolves the virus continues to resides in certain nerve cells. It may remain latent for many years. It may also re-activate, many years later, and cause shingles which is a painful skin rash. How the virus remains latent in the body is not well understood.
Owner Phenotyping Groups:
View Phenotyping Groups:
Final
HIV
Algorithm for the identification of all patients aged 13 or older with HIV in an electronic health record dataset.
Final
Identification of Fibromyalgia Patients in a Rheumatoid Arthritis Cohort
Fibromyalgia has been estimated to affect 12-17% of rheumatoid arthritis patients (1, 2).
This algorithm was created to identify fibromyalgia patients in a population of rheumatoid arthritis patients. The gold standard used for diagnosis of fibromyalgia was that the treating rheumatologist made a clinical diagnosis of fibromyalgia. Rheumatoid arthritis patients were identified by using a previously validated algorithm (3).
Algorithm included the following conditions:
Owner Phenotyping Groups:
Final
Intellectual Disability
Owner Phenotyping Groups:
View Phenotyping Groups:
Final